Pfizer, Janssen Alzheimer Therapy Misses Endpoint

Discontinues development of IV formulation

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pfizer and Janssen AI, partners in the Alzheimer’s Immunotherapy Program (AIP), released the co-primary clinical endpoints in the Janssen AIP Phase III trial of intravenous bapineuzumab in patients with mild-to-moderate Alzheimer’s disease who do not carry the ApoE4 (apolipoprotein E epsilon 4) genotype. The change in cognitive and functional performance compared to placebo, were not met, and the Janssen AI and Pfizer Joint Steering Committee for the AIP has discontinued all other bapineuzumab I...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters